Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Pedro Cahn
Observed names:
Cahn Pedro,
Cahn, Pedro,
P Cahn,
P. Cahn
Institution:
Fundación Huésped
Observed institution:
Fundación Huésped
OpenAlex ID:
A5062484110
Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial
2019
·
Kelly E Dooley
, Richard Kaplan
, et al.
·
Clinical Infectious Diseases
·
137
PDF
Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis
2011
·
Sandra Mathis
, Bettina Khanlari
, et al.
·
PLoS ONE
·
111
PDF
Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial
2006
·
P. Cahn
, J. Villacian
, et al.
·
Clinical Infectious Diseases
·
89
A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial
2005
·
for the MaxCmin2 trial group
, W Belloso
, et al.
·
Antiviral Therapy
·
71
PDF
Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study
2015
·
Carina Cesar
, Cathy A Jenkins
, et al.
·
The Lancet HIV
·
34
Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine
2009
·
P. Cahn
, M. A. Wainberg
·
Journal of Antimicrobial Chemotherapy
·
26
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process
2025
·
Chloe Orkin
, Amy Paterson
, et al.
·
The Lancet HIV
·
22
PDF
Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial
2026
·
Chloe Orkin
, Peter J Ruane
, et al.
·
The Lancet
·
14
Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial
2026
·
Amy E Colson
, Princy N Kumar
, et al.
·
The Lancet
·
9
Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
2026
·
Eric G Meissner
, Moti Ramgopal
, et al.
·
The Lancet HIV
·
5
Comparable efficacy and safety of dolutegravir/lamivudine to a three-drug regimen among ARV naive people living with HIV with CD4 <200/mm3 : the DOLCE study
2024
·
Figueroa, Maria Ines
, Brites, Carlos
, et al.
·
Lume (Universidade Federal do Rio Grande do Sul)
·
5
PDF
Tuberculosis treatment intermittency in the continuation phase and mortality in HIV-positive persons receiving antiretroviral therapy
2022
·
Brenda Crabtree-Ramirez
, Cathy A. Jenkins
, et al.
·
BMC Infectious Diseases
·
4
PDF
No Evidence of HIV-2 Infection in Argentina
1990
·
Gast??n Picchio
, Guillermo Muchinik
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
3
PDF
The Caribbean, Central and South America Network for HIV Epidemiology: 20 Years of HIV Research in the Region
2026
·
Jessica L. Castilho
, Stephany N. Duda
, et al.
·
Journal of the International AIDS Society
·
2
PDF
Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial
2026
·
Dariia Vyshenska
, Jonathan C Reed
, et al.
·
The Lancet Microbe
·
1
Changing to a once-a-day single pill of bictegravir/lenacapavir from complex HIV treatment: a plain language summary of the ARTISTRY-1 study up to 1 year
2026
·
Chloe Orkin
, Peter J. Ruane
, et al.
·
Figshare
Latin America and the Caribbean: Socioeconomic Realities and Implications for Health and HIV Responses
2026
·
Claudia P. Cortes
, Carmen Pérez Casas
, et al.
·
Journal of the International AIDS Society
PDF
Penile human papilloma virus (HPV) in high risk populations with and without HIV: Epidemiological insights from Argentina
2026
·
Diego Daniel Salusso
, Ana Gun
, et al.
·
International Journal of STD & AIDS
Effectiveness of boosted lopinavir versus boosted atazanavir in HIV-1 infected patients switching to second-line antiretroviral therapy following failure of an NNRTI first line ART in a low/middle-income setting, a retrospective cohort study: the BaLANCe study
2018
·
C. Cesar
, M.J. Rolon
, et al.
·
International Journal of Infectious Diseases
PDF
Show more works
View as search
Works count:
19
Citation count:
533
H-index:
9
I10-index:
8
Year
Topic
Type